$NTGN News
Last published 2y ago
- 2y agoKRONMACKMXCTPHVS+4Vicore Expands and Strengthens its Board of DirectorsACCESS NewswireSTOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
- 5y agoPBYINTGNONK Therapeutics Appoints Hugh O’Dowd as Independent ChairmanBusiness WireGALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors.
- 6y agoINFINTGNInfinity Pharmaceuticals Provides Company Update and First Quarter 2020 Financial ResultsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2020 financial results and provided an update on the Company, including its first quarter progress with IPI-549, the Company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase ...
- 6y agoBNTXNTGNBioNTech Announces Full Year 2019 Financial Results and Corporate UpdateGlobeNewswireBNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020COVID-19 vaccine program BNT162 set to enter the clinic in April...
- 6y agoINFINTGNInfinity Pharmaceuticals Augments Board of Directors with Appointment of Richard Gaynor, M.D.Business WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today the appointment of Richard Gaynor, M.D. to its Board of Directors, effective March 16, 2020.
- 6y agoNTGNLifshitz & Miller LLP Announces Investigation of Neon Therapeutics, Inc., Stein Mart, Inc., and Taubman Centers, Inc.GlobeNewswireNEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the...
- 6y agoNTGNNeon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateGlobeNewswireCAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided...
- 6y agoNTGNHXLFSBWMGIMoore Kuehn, PLLC Encourages NTGN, HXL, FSB, and WMGI Investors to Contact FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the...
- 6y agoBNTXNTGNBioNTech to acquire Neon to strengthen global leadership position in T cell therapiesGlobeNewswireFurther expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates...
- 6y agoBNTXNTGNBioNTech to acquire Neon to strengthen global leadership position in T cell therapiesGlobeNewswireFurther expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates...
- 6y agoNTGNNeon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01GlobeNewswireCAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced that it has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for...
- 6y agoNTGNNeon Therapeutics Announces New Strategic Focus on Novel T Cell ProgramsGlobeNewswireLead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors Corporate restructuring effected to focus resources while exploring...
- 7y agoNTGNNeon Therapeutics Reports Third Quarter 2019 Financial Results and Recent HighlightsGlobeNewswireCAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported...